Home Medicine Efficacy and Safety of Inhaled Human Insulin (Exu hera®) Compared to Subcutaneous Insulin in Children Ages 6 to 11 Years with Type 1 Diabetes Mellitus: Results of a 3-Month, Randomized, Parallel Trial
Article
Licensed
Unlicensed Requires Authentication

Efficacy and Safety of Inhaled Human Insulin (Exu hera®) Compared to Subcutaneous Insulin in Children Ages 6 to 11 Years with Type 1 Diabetes Mellitus: Results of a 3-Month, Randomized, Parallel Trial

  • EMAIL logo , , , , and
Published/Copyright: October 22, 2020

Abstract

Aim: To compare the efficacy and safety of Exubera® (EXU) with subcutaneous (SC) insulin in children, ages 6-11 years, with type 1 diabetes mellitus. Design and Methods: 121 children were randomized to receive EXU or SC insulin, plus intermediate/ long-acting insulin for 12 weeks. Change in HbA1c was the primary efficacy endpoint. Results: Decreases from baseline HbA1c were comparable between treatment groups ( difference between adjusted mean decrease from baseline [EXU - SC insulin], -0.23 [95% CI, -0.49, 0.03]). Differences between groups on pulmonary function tests were small and not significant. Mild to moderate cough occurred in 24.6% of EXU versus 6.8% of SC insulin patients. The risk for hypoglycemia was comparable between EXU and SC insulin (relative risk 0.88 [95% CI, 0.71, 1.11]). Increased insulin antibodies with EXU were not associated with clinical findings. Conclusion: The efficacy and safety profiles shown in this study are the foundation for further investigation of EXU in this population.

Published Online: 2020-10-22
Published in Print: 2008-06-01

© 2020 by Walter de Gruyter Berlin/Boston

Articles in the same Issue

  1. TITLE
  2. TABLE OF CONTENTS
  3. EDITORIAL. Why the Consensus for Consensus?
  4. REVIEW. Translating Transition: A Critical Review of the Diabetes Literature
  5. SOCIETY NEWS. VanWyk Award Acceptance Speech, May 5, 2008
  6. IMAGES IN PEDIATRIC ENDOCRINOLOGY. Pseudopuberty and Juvenile Hypothyroidism
  7. ORIGINAL CONTRIBUTIONS
  8. Long-term Follow-up of Patients with Congenital Hyperinsulinism in Austria
  9. An Analysis of Predictive Factors for the Conversion from Premature Thelarche into Complete Central Precocious Puberty
  10. Propylthiouracil Associated Antineutrophil Cytoplasmic Antibodies (ANCA) in Patients with Childhood Onset Graves' Disease
  11. Molecular Analysis of the AR and SRD5A2 Genes in Patients with 46,XY Disorders of Sex Development
  12. Efficacy and Safety of Inhaled Human Insulin (Exu hera®) Compared to Subcutaneous Insulin in Children Ages 6 to 11 Years with Type 1 Diabetes Mellitus: Results of a 3-Month, Randomized, Parallel Trial
  13. Usefulness of Growth Hormone (GH) Stimulation Tests and IGF-1 Concentration Measurement in GH Deficiency Diagnosis
  14. Hyperglycemia and Hypoinsulinemia in Patients with Fanconi-Bickel Syndrome
  15. PATIENT REPORT LETTERS
  16. Glycogen Storage Disease Type Ilia Presenting as Non-Ketotic Hypoglycemia: Use of a Newly Approved Commercially Available Mutation Analysis to Non-Invasively Confirm the Diagnosis
  17. Clinical and Laboratory Findings of Two Newborns with Wiedemann-Rautenstrauch Syndrome: Additional Features, Evaluation of Bone Turnover and Review of the Literature
  18. Congenital Nephrotic Syndrome and Persistent Hypothyroidism After Bilateral Nephrectomy
  19. LETTER TO THE EDITOR
  20. Re: Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents (J Pediatr Endocrinol Metab 2007; 20: 1125-1136)
  21. The Incidence of Glucose Disorders Related to Cystic Fibrosis Could Be Higher with Current Criteria (Re: Carbohydrate Metabolism Changes in Cystic Fibrosis. J Pediatr Endocrinol Metab 2007; 20: 621-663)
  22. CALENDAR
Downloaded on 24.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2008-210610/html
Scroll to top button